Cover Image
市場調查報告書

樹突狀細胞癌症疫苗的全球市場:投藥數量、價格、臨床實驗趨勢預測

Global Dendritic Cell Cancer Vaccine Market Dosage Price and Clinical Trials Outlook 2024

出版商 KuicK Research 商品編碼 322277
出版日期 內容資訊 英文 255 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
樹突狀細胞癌症疫苗的全球市場:投藥數量、價格、臨床實驗趨勢預測 Global Dendritic Cell Cancer Vaccine Market Dosage Price and Clinical Trials Outlook 2024
出版日期: 2018年03月21日 內容資訊: 英文 255 Pages
簡介

本報告提供全球樹突狀細胞癌症疫苗市場相關分析,產品概要和作用機制、功效,產品價格、投藥數量預測,市場轉變與最新形勢,主要的已上市產品的概要互相比較,臨床實驗開發平台概況 (共63項產品:各企業、各症狀、各相),主要企業的簡介的資訊彙整,為您概述為以下內容。

第1章 樹突狀細胞癌症疫苗:序論

  • 樹突狀細胞癌症疫苗的簡史
  • 樹突狀細胞癌症疫苗:革命的癌症治療藥

第2章 免疫系、癌症的樹突狀細胞所扮演的角色

  • 樹突狀細胞:人體免疫系統不可缺少的部分
  • 樹突狀細胞媒介性免疫,對癌症的效果

第3章 樹突狀細胞癌症疫苗的作用機制

  • 樹突狀細胞疫苗的製造流程
  • 樹突狀細胞疫苗對癌症細胞的作用機制

第4章 認證、已上市樹突狀細胞癌症疫苗:功效,可得性,價格,投藥數量分析

  • Provenge
  • Apceden (Apceden-L,Apceden-O,Apceden-C,Apceden-P)
  • CreaVax RCC

第5章 已上市樹突狀細胞癌症疫苗臨床考察

  • Sipuleucel-T (Provenge)
  • 樹突狀細胞疫苗 (CreaVax-HCC,CreaVax-PC,CreaVax-RCC)
  • 樹突狀細胞活性化細胞激素誘導刺客細胞 - Shanghai Jia Fu Medical

第6章 樹突狀細胞癌症疫苗:臨床實驗開發平台上有潛力的候補藥

  • CreaVax-HCC,CreavAX-PC,CreaVax-BC
  • Rocapuldencel-T
  • MelCancerVac
  • Apceden (Apceden-GBM, Apceden-RCC)
  • Vaccell

第7章 Provenge和其他治療藥的比較分析:前列腺癌症情況

  • Provenge 對 Jevtana
  • Provenge 對 Zytiga

第8章 樹突狀細胞癌症疫苗的市場機會:各地區的分析

  • 北美
  • 印度
  • 韓國
  • 日本

第9章 樹突狀細胞癌症疫苗和其他癌症治療藥的聯合治療

  • 放射治療和的組合
  • 單株抗體和的組合

第10章 全球樹突狀細胞癌症疫苗市場現狀

  • 全球市場趨勢
  • 地區市場考察

第11章 各種癌症對於,有未來潛力的樹突狀細胞疫苗

  • 第三階段的黑色素瘤用樹突狀細胞疫苗
  • 急性骨髓性白血病用樹突狀細胞疫苗
  • 腦瘤用樹突狀細胞疫苗

第12章 全球樹突狀細胞癌症疫苗市場動態

  • 良好的市場參數
  • 市場成長相關課題

第13章 全球樹突狀細胞癌症疫苗市場未來預測

  • 未來技術進步
  • 預測隨著癌症患病者的增加,出現大規模的標的病患人數

第14章 樹突狀細胞癌症疫苗臨床實驗開發平台:概要

第15章 樹突狀細胞癌症疫苗臨床實驗開發平台:各企業、各症狀、各相

  • 未確認
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第16章 競爭環境

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Immunicum
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Glaxo Smith Kline
  • ImmunoCellular Therapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

“Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024” Report Highlight:

  • Role of Dendritic Cells in Immune System & Cancer
  • Price & Dosage Analysis of Marketed Dendritic Cell Cancer Vaccine
  • Availability & Efficacy Analysis
  • Marketed Dendritic Cell Cancer Vaccines Clinical Insight: 3 Vaccines
  • Comparative Assessment of Provenge v/s other Key Therapeutics
  • Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase: 63 Vaccines

Conventional therapies like surgery, radiotherapy and chemotherapies are the initial approaches for treating cancer. However, several researchers indicated that these conventional therapies are unable to treat cancer from its root cause and also produce many adverse effects thus, cannot be considered as a future of cancer therapy. Further findings demonstrated that cancer cells directly affect T-cells of the immune system and suppresses the immune activity against it resulting in uninhibited growth of cancer cells. Such incidences triggered the era of modern cancer therapy.

Advances in cellular technologies initiated the research towards exploitation of immune cells for the development of advanced vaccines for treating cancer. One of the cells which are found to be the most attractive target for developing therapeutic vaccines are Dendritic cells as they have the ability to present multiple antigens which are most suited to be a therapy for a multi-cause disease like cancer.

Dendritic cell cancer vaccines have gained significant importance in the market with the approval of first dendritic cell cancer vaccine for metastatic prostate cancer called Provenge. Provenge was approved almost a decade ago and has generated high revenues for the pharmaceutical companies. Dendritic cell vaccines became one of the most promising approaches as it works by boosting up the immune system which in turn will cause no or minimal side effects. Furthermore, cancer is disease with multiple causes and risk factors; researchers stated that instead of preventive vaccines, effective therapeutic vaccines can be developed to treat cancer.

Followed by the approval of Provenge, several similar products were developed for other indications in different regions of the world including CreaVax in South Korea for prostate and kidney cancer and Apceden in India for multiple solid tumors. Additionally, a wide range of dendritic cell vaccines entered in different phases of clinical pipeline such as Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America and Rocapuldencel-T in US etc. All these dendritic cell cancer vaccines are expected to be approved and commercialized and enhance the Global Dendritic cell vaccine market.

Dendritic cell vaccine is the fastest growing segment of cancer vaccine market with other classes of vaccine like peptide vaccines, HPV vaccine, HBV vaccines etc. Dendritic cell vaccines are more specific for treating cancer while others are limited to the treatment of chronic conditions which can cause cancer. Additionally, development of dendritic cell vaccine has been one of the fastest growing sectors amongst all and has resulted in a strong clinical pipeline with more than 60 products in different phases of clinical trials.

Moreover dendritic cell vaccines are unique of its kind which is specifically approved for advanced stages of cancer. Lack of availability of targeted therapies for advance stage of diseases, highly unmet medical needs of metastatic cancer patients indicates exponential rise in the demand for dendritic cell cancer vaccines. Furthermore, commercial successes of Provenge which is available in more than 35 countries; CreaVax in South Korea due to large target patient base has resulted in significant growth of the market.

Increasing prevalence of cancer around the globe will fuel the commercial success of unique dendritic cell vaccines. For instance, in 2018 more than 70000 and 120000 people are expected to be affected by renal cell carcinoma in US and Europe respectively which will result in great market success of Rocapuldencel-T in the coming future. Additionally, nearly 1 Million new incidences of cancer are expected to occur in Japan in 2018 which will fuel the dendritic cell cancer vaccine market in this region.

Moreover, dendritic cell vaccines are considered to be the future of cancer therapy. With the advancement in technology and better understanding of cancer cells, dendritic cells can be used as a preventive measure in the coming future. Additionally, dendritic cell cancer vaccines are one of the safest methods to treat cancer as they boost patient's own immune system by presenting and activating specific antigens at the tumor site. Additionally, presence of a wide range of antigens in human immune system and cancer cells provides opportunities for the development of a wide range of unique products.

Table of Contents

1. Prologue to Dendritic Cell Cancer Vaccine

  • 1.1. Historical Overview of Dendritic Cell Cancer Vaccine
  • 1.2. Dendritic Cell Vaccines: A Revolutionary Cancer Therapy

2. Role of Dendritic Cells in Immune System & Cancer

  • 2.1. Dendritic Cell: Integral Part of Human Immune System
  • 2.2. Effects of Cancer on Dendritic Cell Mediated Immunity

3. Mechanism of Action of Dendritic Cell Cancer Vaccines

  • 3.1. Process Involved in Manufacturing Dendritic Cell Vaccine
  • 3.2. Understanding Working Mechanism of Dendritic Cell Vaccine against Cancer Cells

4. Commercially Approved Dendritic Cell Cancer Vaccine: Efficacy, Availability, Price & Dosage Analysis

  • 4.1. Provenge
    • 4.1.1. Clinical Efficacy
    • 4.1.2. Availability, Dosage & Treatment Schedule
    • 4.1.3. Treatment Cost Analysis
    • 4.1.4. Manufacturing Cost & Market Worth
  • 4.2. Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
    • 4.2.1. Clinical Efficacy
    • 4.2.2. Availability, Dosage & Treatment Schedule
  • 4.3. CreaVax RCC
    • 4.3.1. Availability, Dosage & Treatment Schedule
    • 4.3.2. Manufacturing Cost Process & Involved Technologies

5. Marketed Dendritic Cell Cancer Vaccines Clinical Insight

  • 5.1. Sipuleucel-T (Provenge)
  • 5.2. Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
  • 5.3. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

6. Promising Candidates in Dendritic Cell Cancer Vaccine in Clinical Pipeline

  • 6.1. CreaVax-HCC, CreavAX-PC, CreaVax-BC
  • 6.2. Rocapuldencel-T
  • 6.3. MelCancerVac
  • 6.4. Apceden (Apceden-GBM, Apceden-RCC)
  • 6.5. Vaccell

7. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer

  • 7.1. Provenge v/s Jevtana
    • 7.1.1. Clinical Efficacy
    • 7.1.2. Treatment Course & Dosage
    • 7.1.3. Therapy Price Analysis
  • 7.2. Provenge v/s Zytiga
    • 7.2.1. Clinical Efficacy
    • 7.2.2. Treatment Course & Dosage
    • 7.2.3. Therapy Price Analysis

8. Dendritic Cell Cancer Vaccine Market Opportunity Regional Analysis

  • 8.1. North America
  • 8.2. India
  • 8.3. South Korea
  • 8.4. Japan

9. Dendritic Cell Cancer Vaccine Combination Therapy with other Cancer Therapies

  • 9.1. Dendritic Cell Cancer Vaccine with Radiotherapy
  • 9.2. Dendritic Cell Cancer Vaccine with Monoclonal Antibodies

10. Global Dendritic Cell Cancer Vaccine Current Market Overview

  • 10.1. Global Dendritic Cell Cancer Vaccine Market Trends
  • 10.2. Global Dendritic Cell Vaccine Market Regional Insight
    • 10.2.1. Scope of Dendritic Cell Vaccine Market by Ongoing Researches & Available Advanced Therapies by Region
    • 10.2.2. Scope of Dendritic Cell Vaccine Market by Investments for from Different Sectors
    • 10.2.3. Scope of Reimbursement of Dendritic Cell Cancer Therapy

11. Promising Future of Dendritic Cell Vaccines in Various Cancer

  • 11.1. Dendritic Cell Vaccine in Stage-III Melanoma
  • 11.2. Dendritic Cell Vaccine in Acute Myeloid Leukemia
  • 11.3. Dendritic Cell Vaccine in Brain Tumor

12. Global Dendritic Cell Cancer Vaccine Market Dynamics

  • 12.1. Favorable Market Parameters
  • 12.2. Market Growth Challenges

13. Global Dendritic Cell Cancer Vaccine Market Future Forecast

  • 13.1. Technical Advancements in Dendritic Cell Cancer Vaccine in Future
  • 13.2. Increase in Prevalence of Cancer Providing a Large Target Patient Base for Dendritic Cell Cancer Vaccine in Future

14. Global Dendritic Cell Cancer Vaccines Clinical Pipeline Overview

15. Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase

  • 15.1. Unknown
  • 15.2. Research
  • 15.3. Preclinical
  • 15.4. Clinical
  • 15.5. Phase-I
  • 15.6. Phase-I/II
  • 15.7. Phase-II
  • 15.8. Phase-II/III
  • 15.9. Phase-III

16. Competitive Landscape

  • 16.1. 3M Company
  • 16.2. Activartis
  • 16.3. Argos Therapeutics
  • 16.4. Batavia Bioservices
  • 16.5. Bellicum Pharmaceuticals
  • 16.6. Creagene
  • 16.7. DanDrit Biotech
  • 16.8. DCPrime
  • 16.9. Dendreon Corporation
  • 16.10. Elios Therapeutics
  • 16.11. ImmunoCellular Therapeutics
  • 16.12. Immunicum
  • 16.13. Kiromic
  • 16.14. Medigene
  • 16.15. Merck
  • 16.16. Northwest Biotherapeutics
  • 16.17. Glaxo Smith Kline
  • 16.18. ImmunoCellular Therapeutics
  • 16.19. SOTIO
  • 16.20. Tella Incorporation
  • 16.21. Theravectys
  • 16.22. Vaxil BioTherapeutics

List of Figures

  • Figure 1-1: Milestones in the History of Dendritic Cell Cancer Vaccine Development
  • Figure 2-1: Dendritic Cell in Human Immune System
  • Figure 2-2: Effects of Tumor Cell in Dendritic Cell Dysfunction Leading to Tumor Progression
  • Figure 3-1: Process of Harvesting Dendritic Cell to Develop Vaccines
  • Figure 3-2: General Mechanism of Action of Dendritic Cell Vaccine
  • Figure 4-1: Provenge: Efficacy on the Basis of Clinical Trials
  • Figure 4-2: Provenge - Number of Autologous CD54+ Activated Cells (Million)
  • Figure 4-3: Provenge - Dosage Administration (Minutes)
  • Figure 4-4: Provenge - Average Duration of Therapy
  • Figure 4-5: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
  • Figure 4-6: Provenge - Average Cost (US$/Patient), 2018
  • Figure 4-7: Provenge - Therapy Cost Analysis (US$/Treatment Course), 2018
  • Figure 4-8: Provenge - Company's Expenditure in Drug Development & Therapy Market Value (US$ Billion)
  • Figure 4-9: Apceden - Median Progression-Free Survival in Patients with Solid Tumors (Number of Months), 2018
  • Figure 4-10: Apceden - Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months), 2018
  • Figure 4-11: Apceden v/s Provenge - Adverse Side Effects (%), 2018
  • Figure 4-12: Apceden - Availability of Vial & Vials Required in Apceden Therapy, 2018
  • Figure 4-13: Apceden - Intervals Between Multiple Doses of Treatment
  • Figure 4-14: CreaVax RCC - Approval Analysis by Phase (Year)
  • Figure 4-15: CreaVax RCC - Treatment Course Duration (Weeks), 2018
  • Figure 4-16: CreaVax RCC - Vial Composition Analysis (mL/Dose & Number of Cells/Dose), 2018
  • Figure 4-17: South Korea - CreaVax RCC Patent Cost (US$)
  • Figure 4-18: South Korea - Pharmaceutical Compositions comprising Dendritic Cell Patent Cost (US$)
  • Figure 7-1: Provenge v/s Jevtana - Median Progression Free Survival (Months)
  • Figure 7-2: Provenge v/s Jevtana - Overall Survival (Months)
  • Figure 7-3: Provenge v/s Jevtana - Discontinuation of Treatment in Patients due to Adverse Effects (%)
  • Figure 7-4: Provenge v/s Jevtana - Average Treatment Cycles in Complete Therapy (By Number)
  • Figure 7-5: Provenge v/s Jevtana - Price Analysis (US$/Unit), 2018
  • Figure 7-6: Provenge v/s Jevtana - Price Analysis (US$/Infusion), 2018
  • Figure 7-7: Provenge v/s Jevtana - Average Treatment Cost Analysis (US$), 2018
  • Figure 7-8: Provenge v/s Zytiga - Median Progression Free Survival (Months)
  • Figure 7-9: Provenge v/s Zytiga - Therapy Cost Analysis (US$), 2018
  • Figure 8-1: Global - Rocapuldencel-T Market Opportunity Analysis by Epidemiology of Renal Cell Carcinoma (Number of patients), 2018
  • Figure 8-2: India - Average Lung Cancer Prevalence per Year
  • Figure 8-3: India - Lung Cancer Prevalence by Stage (%), 2018
  • Figure 8-4: India - Apceden Market Opportunity by Epidemiology of Lung Cancer (Number of Patients), 2014-2018
  • Figure 8-5: India - Apceden Market Opportunity by Epidemiology of Ovarian Cancer (Number of Patients), 2014-2018
  • Figure 8-6: India - Apceden Market Opportunity by Epidemiology of Colorectal Cancer (Number of Patients), 2014-2018
  • Figure 8-7: India - Apceden Market Opportunity by Epidemiology of Prostate Cancer (Number of Patients), 2014-2018
  • Figure 8-8: South Korea - Renal Cell Carcinoma Population by Stage of Cancer, (%), 2018
  • Figure 8-9: South Korea - CreaVax RCC Market Opportunity by Renal Cancer Epidemiology (Number of Patients), 2014-2018
  • Figure 8-10: South Korea - Renal Cell Carcinoma Prevalence in Male Population by Number, 2014-2018
  • Figure 8-11: South Korea - Renal Cell Carcinoma Prevalence in Female Population by Number, 2014-2018
  • Figure 8-12: South Korea - Renal Cancer Prevalence by Gender, 2018
  • Figure 8-13: Japan - Epidemiology of Cancer by Gender (%), 2018
  • Figure 8-14: Japan - Epidemiology of Cancer (Number of Patients), 2018
  • Figure 8-15: Japan - Vaccell Market Opportunity by Epidemiology of Pancreatic Cancer by Gender (%), 2018
  • Figure 8-16: Japan - Vaccell market Opportunity by Epidemiology of Pancreatic Cancer (Number of Patients), 2018
  • Figure 8-17: Japan - Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer by Gender (%), 2018
  • Figure 8-18: Japan - Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer (Number of Patients), 2018
  • Figure 8 19: Japan - Vaccell Potential Patient Base by New Incidences, 2018
  • Figure 10-1: Global - Scope of Dendritic Cell Cancer Therapy Market by Ongoing Researches
  • Figure 10-2: Global - Scope of Dendritic Cell Cancer Therapy Market by Approved Advanced Therapies
  • Figure 10-3: Global - Scope of Dendritic Cell Vaccine Cancer Therapy Market by Later Phase Clinical Trials
  • Figure 10-4: Global - Number of Advanced Cancer Therapy Research Studies Funded by Non-Profit Organization
  • Figure 12-1: Factors Favoring Global Dendritic Cell Cancer Vaccine Market
  • Figure 13-1: Global - Dendritic Cell Cancer Vaccine Market Opportunity by Prevalence of Cancer (%)
  • Figure 14-1: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 14-2: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 14-3: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 14-4: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 14-5: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Region/Country (%), 2018 till 2024
  • Figure 14-6: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company (%), 2018 till 2024
  • Figure 16-1: Argos Therapeutics- Clinical Pipeline
  • Figure 16-2: Bellicum Pharmaceuticals Clinical Pipeline
  • Figure 16-3: DCPrime Clinical Pipeline
  • Figure 16-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 16-5: Immunicum Clinical Pipeline
  • Figure 16-6: Medigene Clinical Pipeline
  • Figure 16-7: Northwest Biotherapeutics Clinical Pipeline
  • Figure 16-8: SOTIO Clinical Pipeline
Back to Top